187 related articles for article (PubMed ID: 17881290)
1. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
Khor LY; Bae K; Pollack A; Hammond ME; Grignon DJ; Venkatesan VM; Rosenthal SA; Ritter MA; Sandler HM; Hanks GE; Shipley WU; Dicker AP
Lancet Oncol; 2007 Oct; 8(10):912-20. PubMed ID: 17881290
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
[TBL] [Abstract][Full Text] [Related]
3. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; San-Segundo CG; Rodríguez MÁC; Solé JM; Olivé AP; Casas F; Boladeras A; de Vidales CM; de la Torre MLV; Vara S; Sanz JL; Calvo FA
Lancet Oncol; 2022 May; 23(5):671-681. PubMed ID: 35427469
[TBL] [Abstract][Full Text] [Related]
4. The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.
Pollack A; Bae K; Khor LY; Al-Saleem T; Hammond ME; Venkatesan V; Byhardt RW; Asbell SO; Shipley WU; Sandler HM
Clin Cancer Res; 2009 Sep; 15(17):5478-84. PubMed ID: 19706804
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
Chakravarti A; DeSilvio M; Zhang M; Grignon D; Rosenthal S; Asbell SO; Hanks G; Sandler HM; Khor LY; Pollack A; Shipley W;
J Clin Oncol; 2007 Jul; 25(21):3082-9. PubMed ID: 17634487
[TBL] [Abstract][Full Text] [Related]
6. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
Khor LY; Moughan J; Al-Saleem T; Hammond EH; Venkatesan V; Rosenthal SA; Ritter MA; Sandler HM; Hanks GE; Shipley WU; Pollack A
Clin Cancer Res; 2007 Jun; 13(12):3585-90. PubMed ID: 17575222
[TBL] [Abstract][Full Text] [Related]
8. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
Che M; DeSilvio M; Pollack A; Grignon DJ; Venkatesan VM; Hanks GE; Sandler HM;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1117-23. PubMed ID: 17689883
[TBL] [Abstract][Full Text] [Related]
10. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?
Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659
[TBL] [Abstract][Full Text] [Related]
11. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
12. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
[TBL] [Abstract][Full Text] [Related]
13. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
14. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.
Denham JW; Kumar M; Gleeson PS; Lamb DS; Joseph D; Atkinson C; Matthews J; Tai KH; Spry NA; Christie D; Turner S; Greer PB; D'Este C; Steigler A
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):404-11. PubMed ID: 19176272
[TBL] [Abstract][Full Text] [Related]
15. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
Lawton CAF; Lin X; Hanks GE; Lepor H; Grignon DJ; Brereton HD; Bedi M; Rosenthal SA; Zeitzer KL; Venkatesan VM; Horwitz EM; Pisansky TM; Kim H; Parliament MB; Rabinovitch R; Roach M; Kwok Y; Dignam JJ; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):296-303. PubMed ID: 28463149
[TBL] [Abstract][Full Text] [Related]
16. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581
[TBL] [Abstract][Full Text] [Related]
17. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
[TBL] [Abstract][Full Text] [Related]
18. Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy.
Wilke DR; Krahn M; Tomlinson G; Bezjak A; Rutledge R; Warde P
Cancer; 2010 Apr; 116(8):1909-17. PubMed ID: 20162716
[TBL] [Abstract][Full Text] [Related]
19. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
20. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; González-San Segundo C; Cabeza Rodriguez MA; Macías V; Pedro Olive A; Casas F; Boladeras A; Martín de Vidales C; Vázquez de la Torre ML; Calvo FA
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):341-348. PubMed ID: 27598804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
